暗语
发表于 2025-3-30 10:00:35
Manfred Feilmeierrates (Sialysation, HEPtune) or hydrophilic amino acid polymers (XTEN or PASylation). Use of these technologies to engineer long-acting biobetters with higher efficacy and improved convenience for patients not only opens new treatment options but also offers profitable market opportunities.
thalamus
发表于 2025-3-30 15:24:37
Manfred Feilmeierase (IDUA) lysosomal enzyme, and MPS Type II is caused by mutations in the iduronate 2-sulfatase (IDS) lysosomal enzyme. Both of these diseases have prominent CNS manifestations. This chapter describes biobetter forms of these recombinant enzymes, and the drug development of IgG-IDUA and IgG-IDS fus
女上瘾
发表于 2025-3-30 18:29:13
http://reply.papertrans.cn/44/4303/430243/430243_53.png
ACTIN
发表于 2025-3-30 21:53:31
Manfred Feilmeierase (IDUA) lysosomal enzyme, and MPS Type II is caused by mutations in the iduronate 2-sulfatase (IDS) lysosomal enzyme. Both of these diseases have prominent CNS manifestations. This chapter describes biobetter forms of these recombinant enzymes, and the drug development of IgG-IDUA and IgG-IDS fus
Paraplegia
发表于 2025-3-31 04:53:47
Manfred Feilmeierd only delays the eventual requirement of these patients for ambulatory and ventilator support. This summary will review the recent developments aimed at improving the targeting of new and existing therapeutics to skeletal muscle to reduce the aberrant glycogen load and eliminate muscle damage.